These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 29277234)

  • 21. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions.
    Mauri L; Kereiakes DJ; Normand SL; Wiviott SD; Cohen DJ; Holmes DR; Bangalore S; Cutlip DE; Pencina M; Massaro JM
    Am Heart J; 2010 Dec; 160(6):1035-41, 1041.e1. PubMed ID: 21146655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correction to: 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guidelineon Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery.
    Circulation; 2016 Sep; 134(10):e192-4. PubMed ID: 27601566
    [No Abstract]   [Full Text] [Related]  

  • 23. [The European Society of Cardiology (ESC) guidelines for percutaneous coronary interventions (PCI). Three case reports].
    Silber S; Richartz BM; Brilmayer M;
    Herz; 2006 Dec; 31(9):836-46, 848. PubMed ID: 17180646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implications of new ESC/EACTS guidelines on myocardial revascularization for patients with multivessel coronary artery disease.
    Ribichini F; Taggart D
    Interact Cardiovasc Thorac Surg; 2011 May; 12(5):663-6. PubMed ID: 21555430
    [No Abstract]   [Full Text] [Related]  

  • 25. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial.
    Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Kang SJ; Park SJ; Lee JH; Choi SW; Seong IW; Lee NH; Cho YH; Shin WY; Lee SJ; Lee SW; Hyon MS; Bang DW; Choi YJ; Kim HS; Lee BK; Lee K; Park HK; Park CB; Lee SG; Kim MK; Park KH; Park WJ;
    J Am Coll Cardiol; 2011 Mar; 57(11):1264-70. PubMed ID: 21392640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 2010 focused update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association.
    Dickstein K; Vardas PE; Auricchio A; Daubert JC; Linde C; McMurray J; Ponikowski P; Priori SG; Sutton R; van Veldhuisen DJ; ;
    Eur J Heart Fail; 2010 Nov; 12(11):1143-53. PubMed ID: 20965877
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis.
    Panchal HB; Shah T; Patel P; Albalbissi K; Molnar J; Coffey B; Khosla S; Ramu V
    J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):533-43. PubMed ID: 23872509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
    Tanguay JF; Bell AD; Ackman ML; Bauer RD; Cartier R; Chan WS; Douketis J; Roussin A; Schnell G; Verma S; Wong G; Mehta SR;
    Can J Cardiol; 2013 Nov; 29(11):1334-45. PubMed ID: 23978596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Updates in antiplatelet agents used in cardiovascular diseases.
    Cheng JW
    J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):514-24. PubMed ID: 24213473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.
    Wenaweser P; Eshtehardi P; Abrecht L; Zwahlen M; Schmidlin K; Windecker S; Meier B; Haeberli A; Hess OM
    Thromb Haemost; 2010 Sep; 104(3):554-62. PubMed ID: 20664903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual Antiplatelet Therapy for 6 Months vs 12 Months After New-generation Drug-eluting Stent Implantation: Matched Analysis of ESTROFA-DAPT and ESTROFA-2.
    de la Torre Hernández JM; Oteo Domínguez JF; Hernández F; García Camarero T; Abdul-Jawad Altisent O; Rivero Crespo F; Cascón JD; Zavala G; Gimeno F; Arrebola Moreno AL; Andraka L; Gómez Menchero A; Bosa F; Carrillo X; Sánchez Recalde Á; Alfonso F; Pérez de Prado A; López Palop R; Sanchis J; Diarte de Miguel JA; Jiménez Navarro M; Muñoz L; Ramírez Moreno A; Tizón Marcos H;
    Rev Esp Cardiol (Engl Ed); 2015 Oct; 68(10):838-45. PubMed ID: 26072146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term effect of dual antiplatelet treatment after off-pump coronary artery bypass grafting.
    López J; Morales C; Avanzas P; Callejo F; Hernández-Vaquero D; Llosa JC
    J Card Surg; 2013 Jul; 28(4):366-72. PubMed ID: 23879339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The new 2011 ACCF/AHA Guidelines on Coronary Artery Bypass Grafting surgery: are they different from the 2010 ESC/EACTS Guidelines on Myocardial Revascularisation?
    Kolh P; Sousa Uva M; Wijns W
    EuroIntervention; 2012 May; 8(1):33-4. PubMed ID: 22580246
    [No Abstract]   [Full Text] [Related]  

  • 34. Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (ÖGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC).
    Korte W; Cattaneo M; Chassot PG; Eichinger S; von Heymann C; Hofmann N; Rickli H; Spannagl M; Ziegler B; Verheugt F; Huber K
    Thromb Haemost; 2011 May; 105(5):743-9. PubMed ID: 21437351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Joint ESC/EACTS guidelines on myocardial revascularization.
    Kolh P; Wijns W
    J Cardiovasc Med (Hagerstown); 2011 Apr; 12(4):264-7. PubMed ID: 21372739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy.
    Kereiakes DJ; Yeh RW; Massaro JM; Driscoll-Shempp P; Cutlip DE; Steg PG; Gershlick AH; Darius H; Meredith IT; Ormiston J; Tanguay JF; Windecker S; Garratt KN; Kandzari DE; Lee DP; Simon DI; Iancu AC; Trebacz J; Mauri L;
    JACC Cardiovasc Interv; 2015 Oct; 8(12):1552-62. PubMed ID: 26493248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New oral anticoagulants and dual antiplatelet therapy: Focus on apixaban.
    Pelliccia F; Rollini F; Marazzi G; Greco C; Gaudio C; Angiolillo DJ; Rosano G
    Int J Cardiol; 2016 Dec; 225():154-158. PubMed ID: 27723533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.
    Siasos G; Oikonomou E; Zaromitidou M; Kioufis S; Kokkou E; Mourouzis K; Vlasis K; Vavuranakis M; Stone PH; Papavassiliou AG; Tousoulis D
    Atherosclerosis; 2015 Sep; 242(1):102-8. PubMed ID: 26188531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome.
    Paravattil B; Elewa H
    J Cardiovasc Pharmacol Ther; 2017 Jul; 22(4):347-355. PubMed ID: 28587584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy : The ROMAN (RanOlazine vs. aMlodipine on platelet reactivity in stable patients with CAD treated with dual ANtiplatelet therapy) study.
    Pelliccia F; Greco C; Gaudio C; Rosano G; Vitale C; Marazzi G; Rollini F; Angiolillo DJ
    J Thromb Thrombolysis; 2015 Oct; 40(3):331-9. PubMed ID: 25761430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.